JP Morgan 2025: Incyte expects period of ‘defining catalysts’
Incyte told JP Morgan attendees of plans for four launches in 2025, beginning with its FDA-approved Niktimvo for chronic GvHD.
Incyte told JP Morgan attendees of plans for four launches in 2025, beginning with its FDA-approved Niktimvo for chronic GvHD.
What's Your Reaction?
